Genetic Analysis of A Multifocal Glioblastoma Multiforme: A Suitable Tool to Gain New Aspects in Glioma Development

Neurosurgery

Volumn 53, Issue 6, 2003, Pages 1377-1384

  Krex, Dietmar ^a   Mohr, Brigitte ^a   Appelt, Hella ^a   Schackert, Hans K ^a   Schackert, Gabriele ^a   Waziri, Allen E ^b   Bruce, Jeffrey N ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b NONE

Author keywords

Chromosome aberration; Cytogenetics; Glioma; P53; Spectral karyotyping

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P73; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PATIENT; CANCER TISSUE; CASE REPORT; CELL ISOLATION; CELL LINE; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 15; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERPHASE; KARYOTYPING; MALE; MULTIPLE CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TUMOR VOLUME;

EID: 0344443360     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000093426.29236.86     Document Type: Article

References (33)

1. Amler LC, Bauer A, Corvi R, Dihlmann S, Praml C, Cavenee WK, Schwab M, Hampton GM: Identification and characterization of novel genes located at the t(1;15)(p36.2;q24) translocation breakpoint in the neuroblastoma cell line NGP. Genomics 64:195-202, 2000.
2. Brunner C, Jung V, Henn W, Zang KD, Urbschat S: Comparative genomic hybridization reveals recurrent enhancements on chromosome 20 and in one case combined amplification sites on 15q24q26 and 20p11p12 in glioblastomas. Cancer Genet Cytogenet 121:124-127, 2000.
3. Casciano I, Marchi JV, Muresu R, Volpi EV, Rozzo C, Opdenakker G, Romani M: Molecular and genetic studies on the region of translocation and duplication in the neuroblastoma cell line NGP at the 1p36.13-p36.32 chromosomal site. Oncogene 12:2101-2108, 1996.
4. Chernova OB, Somerville RP, Cowell JK: A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene 17: 2873-2881, 1998.
5. Davis FG, Freels S, Grutsch J, Barlas S, Brem S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88:1-10, 1998.
6. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nat Genet 4:42-46, 1993.
7. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A: PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16:2259-2264, 1998.
8. Fearon ER, Hamilton SR, Vogelstein B: Clonal analysis of human colorectal tumors. Science 238:193-197, 1987.
9. Frederick L, Wang XY, Eley G, James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383-1387, 2000.
10. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG: p53 gene mutation and ink4a-arf de]etion deletion appear to be two Mutually exclusive events in human glioblastoma. Oncogene 19: 3816-3822, 2000.
11. Goh HS, Yao J, Smith DR: p53 point mutation and survival in colorectal cancer patients. Cancer Res 55:5217-5221, 1995.
12. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994.
13. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49-53, 1991.
14. Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, Han SY, Suzuki T, Shibata H, Kanamaru R, Ishioka C: Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 6:3937-3943, 2000.
15. Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68:820-823, 1971.
16. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G: High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A 97:4174-4179, 2000.
17. Mertens F, Johansson B, Hoglund M, Mitelman F: Chromosomal imbalance maps of malignant solid tumors: A cytogenetic survey of 3185 neoplasms. Cancer Res 57:2765-2780, 1997.
18. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A, Poustka A: DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet 17:32-39, 1997.
19. Morse RP, Darras BT, Ye Z, Wu JK: Clonal analysis of human astrocytomas. J Neurooncol 21:151-157, 1994.
20. Nakamura H, Yoshida M, Tsuiki H, Ito K, Ueno M, Nakao M, Oka K, Tada M, Kochi M, Kuratsu J, Ushio Y, Saya H: Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. Oncogene 16:1009-1019, 1998.
21. Raithatha SA, Muzik H, Rewcastle NB, Johnston RN, Edwards DR, Forsyth PA: Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro-oncology 2:145-150, 2000.
22. Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH: Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324-1330, 1994.
23. Ryan KM, Phillips AC, Vousden KH: Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13:332-337, 2001.
24. Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodemann HP, Bamberg M: Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol 49:197-203, 2000.
25. Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T: Multicolor spectral karyotyping of human chromosomes. Science 273:494-497, 1996.
26. Schrock E, Thiel G, Lozanova T, du Manoir S, Meffert MC, Jauch A, Speicher MR, Nurnberg P, Vogel S, Janisch W, Donis-Keller H, Ried T, Witkowski R, Cremer T: Comparative genomic hybridization of human malignant gliomas reveals multiple amplification sites and nonrandom chromosomal gains and losses. Am J Pathol 144:1203-1218, 1994.
27. Schwab M, Praml C, Amler LC: Genomic instability in 1p and human malignancies. Genes Chromosomes Cancer 16:211-229, 1996.
28. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B: Clonal origin bladder cancer. N Engl J Med 326:737-740, 1992.
29. Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, Haugen A: p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 6:1031-1037, 2000.
30. von Deimling A, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15:328-338, 1995.
31. Wechsler DS, Shelly CA, Petroff CA, Dang CV: MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res 57:4905-4912, 1997.
32. Weissenberger J, Steinbach JP, Malin G, Spada S, Rulicke T, Aguzzi A: Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 14:2005-2013, 1997.
33. You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R, Chin L, DePinho RA: Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A 99:1455-1460, 2002.